How to Choose Clinical Software

From EHR replacement to AI-powered clinical decision support — what procurement officers and biomed engineers need to know before signing.

What this is and who buys it

Clinical software spans electronic health records (EHRs/EMRs), clinical decision support (CDS), e-prescribing platforms, practice management systems, telehealth infrastructure, and Software as a Medical Device (SaMD) — any application that documents, analyzes, or acts on patient data. The category is unusually wide: the same regulatory label covers a solo-practice scheduling tool and an AI algorithm that flags sepsis risk in an ICU. Over 96% of U.S. hospitals and 75% of office-based clinicians already use an ONC-certified EHR [S5], which means most procurement conversations today are about replacement, module expansion, or specialty add-ons rather than first-time deployments.

Who buys it varies enormously. Hospital systems and integrated delivery networks (IDNs) typically have dedicated IT and clinical informatics teams driving large, multi-year programs. Ambulatory practices — FQHCs, specialty clinics, ASCs — often rely on a practice administrator or a part-time biomed consultant. What both share is exposure to the same regulatory requirements and the same vendor lock-in risks, even if the contract values differ by two orders of magnitude.

The market is also in active regulatory transition. The HTI-1 final rule, published in the Federal Register in January 2024, introduces new AI transparency requirements, updates interoperability standards, and resets what "certified" means for decision support tools [S4]. Any procurement initiated today will be operating under those rules by the time the system is live — so requirements written against older criteria are already outdated.

Key decision factors

ONC certification status is the non-negotiable baseline for any platform used in Medicare or Medicaid billing. As of January 1, 2026, the certified baseline shifts from USCDI Version 1 to USCDI Version 3, and decision support intervention (DSI) criteria replace older CDS certification requirements for Promoting Interoperability reporting [S2][S3]. Confirming a vendor's current Certified Health IT Product List (CHPL) ID — not a claimed certification date — is the first document to request.

Interoperability and API architecture determine how well a system will exchange data with labs, pharmacies, referral networks, and patient-facing apps. At minimum, look for HL7 v2, FHIR R4, C-CDA, and SMART on FHIR support. SMART App Launch Implementation Guide v2 replaces v1 after December 31, 2025 [S13], so contracts signed today should explicitly reference the v2 roadmap.

Deployment model has real operational consequences. Cloud-based implementations now account for roughly 85% of new deployments, largely because they reduce on-site hardware and disaster recovery overhead. On-premises licensing can be cheaper over a 7–10 year horizon — estimated five-year TCO of approximately $48,000 per provider versus $58,000 for cloud [S11] — but only when in-house IT capacity genuinely exists to manage patching, backups, and uptime.

Specialty fit is frequently underweighted in RFPs. A platform with excellent primary care templates may require $50,000–$150,000 in customization to adequately serve an oncology or behavioral health workflow. Evaluate specialty-specific order sets, registry reporting hooks, and how the vendor handles procedure documentation rather than relying on generic screenshots.

AI and CDS transparency has moved from a nice-to-have to a compliance requirement. HTI-1 establishes first-of-their-kind transparency requirements for AI and predictive algorithms embedded in certified health IT [S4]. For any embedded predictive feature — sepsis alerts, readmission scores, diagnostic flagging — request model cards, training-data demographics, and bias validation by patient subgroup before contract signature.

Security architecture should meet a minimum floor of TLS encryption for data in transit and AES-256 for data at rest. SOC 2 Type II attestation or HITRUST CSF certification is increasingly table stakes; requests for these documents during due diligence are now standard and a refusal is itself informative.

What it costs

EHR pricing is notoriously difficult to benchmark because vendors rarely publish list prices, and implementation costs often dwarf license fees. License is typically only 40–60% of total implementation spend [S9]; the remainder covers interfaces, data migration, training, project management, and first-year support.

• Entry tier ($100–$600/provider/month): Cloud SaaS for solo and small practices; total implementation typically $20,000–$65,000 [S10].
• Mid tier ($200–$700/provider/month + one-time costs): Small-to-mid practices; one-time upfront of $1,500–$5,000 for smaller settings; mid-size clinic full implementations range from $65,000–$200,000 [S10][S11].
• Enterprise tier ($500,000–$2M+ and up): Hospital and health system deployments; large enterprise rollouts can reach $80 million or more. Specific vendor pricing at this tier is not publicly verifiable — treat any vendor-quoted figure as a starting point for negotiation, not a market rate.

Common use cases

Clinical software is rarely a single product — it's a portfolio decision. Understanding which use case is actually driving the procurement helps avoid over-buying a platform built for a different environment.

• Ambulatory practices and FQHCs needing a certified EHR, practice management, and patient portal in a single cloud subscription with manageable IT overhead.
• Inpatient hospitals and IDNs requiring CPOE, barcoded medication administration (BCMA), surgical documentation, and ED modules tightly integrated to lab, radiology, and pharmacy.
• Specialty practices — ophthalmology, oncology, behavioral health, PT/OT — where templated workflows, specialty-specific order sets, and quality registry reporting drive measurable ROI.
• SaMD point solutions: radiology image-analysis software that highlights potential abnormalities, glucose monitoring apps that generate clinical alerts, or drug-dosing decision support tools [S1] — these run alongside the EHR and require separate FDA compliance review.

Regulatory and compliance

Two parallel regulatory tracks apply, and conflating them is a common procurement error. The first is ONC certification under the Health IT Certification Program, which is an administrative requirement tied to Medicare and Medicaid incentive programs. The second is FDA oversight of Software as a Medical Device (SaMD), which applies when software is intended to diagnose, treat, or prevent disease independent of a hardware device [S1].

For FDA-regulated SaMD, the risk classification follows the same three-tier structure used for hardware: Class I (lowest risk, often exempt from premarket review), Class II (moderate risk, requires 510(k) or De Novo clearance), and Class III (high risk, requires PMA). In practice, nearly all FDA-authorized AI/ML-enabled clinical software has been cleared as Class II — of 168 AI/ML devices cleared in 2024, all were Class II, with 94.6% via 510(k) [S6][S7]. Relevant standards include IEC 62304 (software lifecycle processes), ISO 14971 (risk management), ISO/IEC 27001 (information security), and the HIPAA Security Rule at 45 CFR 164.302–318 [S12]. CDS tools may qualify for partial exemption under the 21st Century Cures Act, but the boundaries of that exemption are narrower than many vendors imply.

Service, training, and total cost of ownership

Implementation timelines run 6–18 months for ambulatory settings and 18–36 months for hospital go-lives; either estimate can slip without experienced project management on both sides of the table. Training is a significant and often underbudgeted line item — a reasonable ballpark is approximately $1,200 per end user [S9], and go-live productivity losses can range from $20,000 to $100,000 depending on volume and workflow complexity. Data migration alone — moving legacy patient records into the new system — typically costs $20,000–$50,000, depending on record volume and source-system complexity [S11].

First-year maintenance and support costs frequently reach $85,000 or more for practices of any meaningful size [S9]. Beyond year one, plan for quarterly platform updates, annual certification refreshes, and — for SaMD components — ongoing post-market surveillance and algorithm performance monitoring per any FDA-approved Predetermined Change Control Plan (PCCP). Practical software lifespan before major re-platforming is 7–12 years, with a productive ROI horizon of roughly 2.5 years and a modeled net benefit around $23,000 per staff member annually in optimized deployments.

Red flags to watch for

A vendor that cannot produce a current CHPL ID — or references certification under a retired edition — should trigger immediate caution; this is verifiable in minutes on the ONC CHPL database. "AI-powered" clinical features marketed without FDA clearance documentation (when the function meets the SaMD definition) represent both a regulatory risk and a patient safety concern worth escalating before contract execution.

Percentage-of-collections pricing — structures where RCM fees run 3–7% of monthly revenue — can look affordable at practice launch but scale punitively as volumes grow; always model this against a flat per-provider fee over five years before comparing options. Opaque interface fees of $5,000–$25,000 per HL7 or FHIR connection are another common cost-escalation mechanism buried in technical annexes. Finally, any contract that lacks explicit data-export rights in a USCDI-conformant format at termination is a potential information-blocking situation under the HTI-1 rules [S4] — and a negotiating point, not an afterthought.

Questions to ask vendors

1. Provide your CHPL ID and confirm certification to current HTI-1 criteria, including DSI (§170.315(b)(11)) and standardized API (§170.315(g)(10)). What is your roadmap to USCDI v3 and SMART App Launch v2?
2. List every embedded AI or predictive feature with its FDA status (510(k) number, De Novo order, or exempt rationale), training-data demographics, and subgroup validation performance.
3. Provide a fully loaded 5-year TCO: license, implementation, per-interface costs, data migration, training, hosting, and annual support escalators. Are RCM fees percentage-of-collections or flat?
4. What are your contractual SLAs for uptime, P1 incident response, and data-restore RTO/RPO? Provide the last 12 months of actual uptime figures by region.
5. Describe data-export rights at termination: format (FHIR bulk export, C-CDA, CSV), timeline, and cost. Will you provide a complete patient-level archive?
6. Provide your current SOC 2 Type II report, HITRUST CSF certification status, and most recent third-party penetration test executive summary.

Alternatives

Before committing to a full replacement, it is worth rigorously evaluating whether the current system is the actual problem. Workflow redesign, retraining, and targeted module additions frequently deliver more measurable improvement than a rip-and-replace, particularly when clinician adoption — not platform capability — is the root cause of underperformance.

• Cloud SaaS vs. on-premises: Cloud has lower upfront cost but higher long-term cost in many scenarios; on-prem can be more economical over a 7-year horizon only with internal IT capacity to sustain it [S11].
• Integrated suite vs. best-of-breed: Enterprise suites reduce interface complexity but create deep vendor lock-in — two vendors collectively hold over 62% of the U.S. inpatient market [S8], which limits leverage in renewal negotiations. Best-of-breed connected via FHIR APIs can outperform generic EHR modules in high-volume specialty workflows.
• Specialty SaMD point solution vs. EHR module: For oncology regimen management, ophthalmology imaging, or complex anesthesia documentation, a dedicated SaMD platform integrated via FHIR frequently provides better clinical workflow fit than a module bolted onto a generalist EHR.
• In-house vs. vendor support contracts: Hospitals with mature IT organizations can often reduce tier-1/2 support costs by 15–25% through insourcing, retaining vendor contracts only for core platform issues.

Sources

• FDA — Software as a Medical Device (SaMD)
• ONC HTI-1 Final Rule — HealthIT.gov
• HTI-1 Overview Fact Sheet (ASTP/ONC)
• Federal Register — HTI-1 Final Rule (89 FR; Jan 9, 2024)
• ONC Health IT Playbook — Electronic Health Records
• FDA Regulation of Clinical Software in the Era of AI/ML (PMC)
• FDA SaMD Classification: AI & Machine Learning Guide (IntuitionLabs)
• Definitive Healthcare — Hospital EHR Market Share (April 2026)
• EHR Implementation Cost Breakdown (Topflight, 2026)
• EHR Software Cost Guide (RXNT, 2026)
• EHR Implementation Costs (RiverAxe, 2025)
• FDA Guidance on SaMD — Standards Reference (Saraca Solutions)
• Breaking Down HTI-1 (National Rural Health Association)